Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia

Research output: Contribution to journalArticle

Abstract

Hematopoietic stem cell transplantation (bone marrow transplantation [BMT]) is the only curative treatment of severe aplastic anemia. BMT from an human leukocyte antigen (HLA)-matched sibling donor is the standard of care for young patients; immunosuppressive therapy is used for older patients or those lacking matched sibling donors. Patients with refractory or relapsed disease are increasingly treated with HLA haploidentical BMT. Historically, haploidentical BMT led to high rates of graft rejection and graft-versus-host disease. High-dose post transplant cyclophosphamide, which mitigates the risk of graft-versus-host disease, is a major advance. This article provides an overview of the haploidentical BMT approach in severe aplastic anemia.

Original languageEnglish (US)
JournalHematology/Oncology Clinics of North America
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Aplastic Anemia
Bone Marrow Transplantation
Tissue Donors
Graft vs Host Disease
HLA Antigens
Siblings
Hematopoietic Stem Cell Transplantation
Graft Rejection
Standard of Care
Immunosuppressive Agents
Cyclophosphamide
Transplants
Therapeutics

Keywords

  • Cyclophosphamide
  • Graft versus host disease
  • Haploidentical transplant
  • Severe aplastic anemia

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{3b892ae7c5c04e81bc8ff43b4bfff6ae,
title = "Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia",
abstract = "Hematopoietic stem cell transplantation (bone marrow transplantation [BMT]) is the only curative treatment of severe aplastic anemia. BMT from an human leukocyte antigen (HLA)-matched sibling donor is the standard of care for young patients; immunosuppressive therapy is used for older patients or those lacking matched sibling donors. Patients with refractory or relapsed disease are increasingly treated with HLA haploidentical BMT. Historically, haploidentical BMT led to high rates of graft rejection and graft-versus-host disease. High-dose post transplant cyclophosphamide, which mitigates the risk of graft-versus-host disease, is a major advance. This article provides an overview of the haploidentical BMT approach in severe aplastic anemia.",
keywords = "Cyclophosphamide, Graft versus host disease, Haploidentical transplant, Severe aplastic anemia",
author = "Amy Dezern and Brodsky, {Robert A}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.hoc.2018.04.001",
language = "English (US)",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia

AU - Dezern, Amy

AU - Brodsky, Robert A

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hematopoietic stem cell transplantation (bone marrow transplantation [BMT]) is the only curative treatment of severe aplastic anemia. BMT from an human leukocyte antigen (HLA)-matched sibling donor is the standard of care for young patients; immunosuppressive therapy is used for older patients or those lacking matched sibling donors. Patients with refractory or relapsed disease are increasingly treated with HLA haploidentical BMT. Historically, haploidentical BMT led to high rates of graft rejection and graft-versus-host disease. High-dose post transplant cyclophosphamide, which mitigates the risk of graft-versus-host disease, is a major advance. This article provides an overview of the haploidentical BMT approach in severe aplastic anemia.

AB - Hematopoietic stem cell transplantation (bone marrow transplantation [BMT]) is the only curative treatment of severe aplastic anemia. BMT from an human leukocyte antigen (HLA)-matched sibling donor is the standard of care for young patients; immunosuppressive therapy is used for older patients or those lacking matched sibling donors. Patients with refractory or relapsed disease are increasingly treated with HLA haploidentical BMT. Historically, haploidentical BMT led to high rates of graft rejection and graft-versus-host disease. High-dose post transplant cyclophosphamide, which mitigates the risk of graft-versus-host disease, is a major advance. This article provides an overview of the haploidentical BMT approach in severe aplastic anemia.

KW - Cyclophosphamide

KW - Graft versus host disease

KW - Haploidentical transplant

KW - Severe aplastic anemia

UR - http://www.scopus.com/inward/record.url?scp=85047549995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047549995&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2018.04.001

DO - 10.1016/j.hoc.2018.04.001

M3 - Article

C2 - 30047416

AN - SCOPUS:85047549995

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

ER -